Patents by Inventor Philippe Cuniasse

Philippe Cuniasse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cysteine-free efficient Technetium (Tc) or Rhenium (Re) chelating peptide tags and their use
    Patent number: 9234001
    Abstract: The present invention relates to a peptide tag which can be used to bind a Technetium (Tc) or Rhenium (Re) radionuclide to a protein of interest which comprises the peptide tag and allows the imaging of such a tagged protein. In particular the present invention relates to a peptide tag which chelates a Tc or Re atom but which does not comprise a Cysteine residue.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: January 12, 2016
    Assignee: Commissariat a L'Energie Atomique et aux Energies Alternatives
    Inventors: Loïc Le Clainche, Alain Lecoq, Sophie Zinn-Justin, Robert Thai, Michel Masella, Philippe Cuniasse
  • Cysteine-Free Efficient Technetium (Tc) or Rhenium (Re) Chelating Peptide Tags and Their Use
    Publication number: 20110318827
    Abstract: The present invention relates to a peptide tag which can be used to bind a Technetium (Tc) or Rhenium (Re) radionuclide to a protein of interest which comprises the peptide tag and allows the imaging of such a tagged protein. In particular the present invention relates to a peptide tag which chelates a Tc or Re atom but which does not comprise a Cysteine residue.
    Type: Application
    Filed: December 28, 2009
    Publication date: December 29, 2011
    Inventors: Loïc Le Clainche, Alain Lecoq, Sophie Zinn-Justin, Robert Thai, Michel Masella, Philippe Cuniasse
  • Phosphinic pseudo-peptides that may be used as matrix zinc metalloprotease inhibitors
    Patent number: 6630501
    Abstract: The invention relates to pseudo-peptides according to the formula: wherein R1 is a group inhibiting an amine function, or an amino acid residue or peptide with an inhibited terminal amino function, R2 represents the lateral chain of a natural or non-natural amino acid, R3 represents: 1) the lateral chain of a natural amino acid except for Gly and Ala, not substituted or substituted by an aryl group, 2) an aralkyl group, or 3) an alkyl group comprising at least 3 carbon atoms, and R4 represents a lateral chain of natural or non-natural amino acid. They are useful as matrix zinc metalloprotease inhibitors, particularly in the treatment of cancer.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: October 7, 2003
    Assignees: Commissariat a l'energie Atomique, Institut National de la Recherche Medical, Centre National de la Recherche Scientifique
    Inventors: Vincent Dive, Philippe Cuniasse, Marie-Christine Rio, Paul Basset, Athanasios Yotakis, Fabrice Beau, Stamania Vassiliou
  • N-terminal site selective inhibitors of human angiotensin conversion enzyme (ACE)
    Patent number: 6482797
    Abstract: The invention relates to peptide derivatives that can be used as selective inhibitors of the N-terminal site of human angiotensin-converting enzyme. The derivatives comprise the amino acid sequence with the following formula: -Asp-Phe-&PSgr;(PO2CH2)-Ala-Xaa′-  (I) wherein: &PSgr;(PO2CH2) indicates that the peptide bond (CONH) between Phe and Ala has been replaced by the phosphonic bond PO2CH2, and Xaa′ represents an amino acid residue. They can be used in pharmaceutical formulations, particularly to protect haematopoietic strain cells of patients undergoing aggressive chemotherapy or radiotherapy treatment.
    Type: Grant
    Filed: January 30, 2001
    Date of Patent: November 19, 2002
    Assignees: Commissariat A l'Energie Atomique, Institut National de la Sante et de la Recherche Medicale Inserm
    Inventors: Vincent Dive, Joël Cotton, Philippe Cuniasse, Athanasios Yiotakis, Pierre Corvol, Annie Michaud, Marie-Thérèse Chauvet, Joël Menard, Eric Ezan